Andrew Vaillant
Replicor Inc., Canada
Title: Nucleic acid polymers: Application in the treatment of chronic HBV and HBV/HDV infection and potentiating the effects of immunotherapy
Biography
Biography: Andrew Vaillant
Abstract
Nucleic acid polymers (NAPs) have the unique ability to block the release of the hepatitis B surface antigen (HBsAg) from infected hepatocytes and clear HBsAg from the blood of human patients, a critical step in achieving a functional cure in HBV and HBV/HDV infection. Recent data will be presented from the ongoing REP 301 clincal trial (NCT02233075) which is assessing the safety and efficacy of the NAP REP 2139 when used in combination with pegylated interferon alpha 2a in patients with chronic HBV/HDV co-infection. These clinical data demonstrate the unique ability of NAPs to clear circulating HBsAg and HDV in patients. Clearance of HBsAg is accompanied by important immunological impacts: The appearance of anti-HBs, a synergistic improvement in the effiacy of pegylated interferon and the ability to achieve complete control of HBV and HDV infection with a finite course of treatment.
Speaker Presentations
Speaker PPTs Click Here